glaucoma 3A

Summary

glaucoma 3A (MONDO:0009277) is a disease caused by CYP1B1 (GenCC Definitive), with 5 cohort genes.

At a glance

• Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
• Causal gene: CYP1B1 (GenCC Definitive)
• Cohort genes: 5
• ClinVar variants: 196
• Phenotypes (HPO): 19

Clinical features

Epidemiology

Prevalence records

18 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Prevalence at birth	1-9 / 100 000	2.2	Europe	Validated
Prevalence at birth	1-9 / 100 000	2.9	Belgium	Validated
Prevalence at birth	1-9 / 100 000	6.6	France	Validated
Prevalence at birth	1-9 / 100 000	2.8	Malta	Validated
Prevalence at birth	1-9 / 100 000	3.6	Italy	Validated
Prevalence at birth	1-9 / 100 000	5.6	Netherlands	Validated
Prevalence at birth	1-9 / 1 000 000	0.8	Norway	Validated
Prevalence at birth	1-9 / 1 000 000	0.9	Portugal	Validated
Prevalence at birth	1-9 / 100 000	6.5	Spain	Validated
Prevalence at birth	1-9 / 100 000	2.2	United Kingdom	Validated
Prevalence at birth	1-9 / 100 000	3	Ukraine	Validated
Prevalence at birth	1-9 / 100 000	1.5	Switzerland	Validated
Prevalence at birth	1-9 / 100 000	1.4	Poland	Validated
Prevalence at birth	1-9 / 100 000	4.1	Ireland	Validated
Prevalence at birth	1-9 / 100 000	4.1	Germany	Validated
Prevalence at birth	1-9 / 100 000	2.8	Croatia	Validated
Prevalence at birth	1-9 / 100 000	3.4	Austria	Validated
Point prevalence	1-9 / 100 000		Europe	Not yet validated

Signs & symptoms

Clinical features (HPO)

19 HPO clinical features (Orphanet curated; top 19 by frequency):

HPO ID	Term	Frequency
HP:0000501	Glaucoma	Very frequent (80-99%)
HP:0012040	Corneal stromal edema	Very frequent (80-99%)
HP:0000485	Megalocornea	Frequent (30-79%)
HP:0000557	Buphthalmos	Frequent (30-79%)
HP:0000613	Photophobia	Frequent (30-79%)
HP:0000643	Blepharospasm	Frequent (30-79%)
HP:0001089	Iris atrophy	Frequent (30-79%)
HP:0007765	Deep anterior chamber	Frequent (30-79%)
HP:0007906	Ocular hypertension	Frequent (30-79%)
HP:0007957	Corneal opacity	Frequent (30-79%)
HP:0009926	Epiphora	Frequent (30-79%)
HP:0011490	Abnormal Descemet membrane morphology	Frequent (30-79%)
HP:0025751	Reduced anterior scleral thickness	Frequent (30-79%)
HP:0000545	Myopia	Occasional (5-29%)
HP:0000572	Visual loss	Occasional (5-29%)
HP:0000646	Amblyopia	Occasional (5-29%)
HP:0007663	Reduced visual acuity	Occasional (5-29%)
HP:0012803	Anisometropia	Occasional (5-29%)
HP:0100693	Iridodonesis	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	glaucoma 3A
Mondo ID	MONDO:0009277
OMIM	231300
Orphanet	98976
DOID	DOID:11211
NCIT	C148260
UMLS	C1856439
MedGen	383912
GARD	0018224
Is cancer (heuristic)	no

Also known as: buphthalmos · glaucoma 3, primary congenital, A · glaucoma 3, primary congenital, type a · glaucoma 3A, primary open angle, congenital, juvenile, or adult onset · GLC3A · Primary Congenital glaucoma 3A

Data availability: 196 ClinVar variants · 3 GenCC gene-disease records · 1 cell line.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › hereditary glaucoma › congenital glaucoma › primary congenital glaucoma › CYP1B1-related glaucoma with or without anterior segment dysgenesis › glaucoma 3A

Related subtypes (1): anterior segment dysgenesis 6

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

196 retrieved; paginated sample, class counts are floors:

87 uncertain significance, 31 pathogenic, 30 likely pathogenic, 19 conflicting classifications of pathogenicity, 13 benign, 7 likely benign, 6 pathogenic/likely pathogenic, 2 benign/likely benign, 1 not provided

ClinVar	Variant (HGVS)	Gene	Classification	Review
2628067	NM_015692.5(CPAMD8):c.3798_3861+1759del	CPAMD8	Pathogenic	criteria provided, single submitter
1076484	NM_000104.4(CYP1B1):c.840C>A (p.Cys280Ter)	CYP1B1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1120045	NM_000104.4(CYP1B1):c.434_443del (p.Arg145fs)	CYP1B1	Pathogenic	reviewed by expert panel
1254629	NM_000104.4(CYP1B1):c.1310C>T (p.Pro437Leu)	CYP1B1	Pathogenic	reviewed by expert panel
1322184	NM_000104.4(CYP1B1):c.517G>T (p.Glu173Ter)	CYP1B1	Pathogenic	reviewed by expert panel
1339135	NM_000104.4(CYP1B1):c.1044-2A>G	CYP1B1	Pathogenic	reviewed by expert panel
1339668	NM_000104.4(CYP1B1):c.1090G>A (p.Val364Met)	CYP1B1	Pathogenic	reviewed by expert panel
1442930	NM_000104.4(CYP1B1):c.55C>T (p.Gln19Ter)	CYP1B1	Pathogenic	criteria provided, multiple submitters, no conflicts
2203048	NM_000104.4(CYP1B1):c.1168C>A (p.Arg390Ser)	CYP1B1	Pathogenic	reviewed by expert panel
2577219	NM_000104.4(CYP1B1):c.317C>A (p.Ala106Asp)	CYP1B1	Pathogenic	reviewed by expert panel
265390	NM_000104.4(CYP1B1):c.830del (p.Phe276_Leu277insTer)	CYP1B1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2681130	NM_000104.4(CYP1B1):c.872A>G (p.Asp291Gly)	CYP1B1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2681138	NM_000104.4(CYP1B1):c.1140dup (p.Val381fs)	CYP1B1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2687741	NM_000104.4(CYP1B1):c.9del (p.Ser4fs)	CYP1B1	Pathogenic	no assertion criteria provided
2734165	NM_000104.4(CYP1B1):c.243C>G (p.Tyr81Ter)	CYP1B1	Pathogenic	criteria provided, multiple submitters, no conflicts
282564	NM_000104.4(CYP1B1):c.1064_1076del (p.Arg355fs)	CYP1B1	Pathogenic	reviewed by expert panel
3236111	NM_000104.4(CYP1B1):c.83C>A (p.Ser28Ter)	CYP1B1	Pathogenic	criteria provided, single submitter
3236697	NM_000104.4(CYP1B1):c.1333T>A (p.Phe445Ile)	CYP1B1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
335952	NM_000104.4(CYP1B1):c.1168C>T (p.Arg390Cys)	CYP1B1	Pathogenic	reviewed by expert panel
3777763	NC_000002.12:g.38012214_38131522del	CYP1B1	Pathogenic	reviewed by expert panel
417858	NM_000104.4(CYP1B1):c.1063_1075del (p.Arg355fs)	CYP1B1	Pathogenic	no assertion criteria provided
523943	NM_000104.4(CYP1B1):c.535del (p.Ala179fs)	CYP1B1	Pathogenic	reviewed by expert panel
592512	NM_000104.4(CYP1B1):c.1169G>A (p.Arg390His)	CYP1B1	Pathogenic	reviewed by expert panel
68466	NM_000104.4(CYP1B1):c.1200_1209dup (p.Thr404fs)	CYP1B1	Pathogenic	reviewed by expert panel
68468	NM_000104.4(CYP1B1):c.868dup (p.Arg290fs)	CYP1B1	Pathogenic	reviewed by expert panel
7730	NM_000104.4(CYP1B1):c.182G>A (p.Gly61Glu)	CYP1B1	Pathogenic	reviewed by expert panel
7733	NM_000104.4(CYP1B1):c.1405C>T (p.Arg469Trp)	CYP1B1	Pathogenic	reviewed by expert panel
7735	NM_000104.4(CYP1B1):c.1159G>A (p.Glu387Lys)	CYP1B1	Pathogenic	reviewed by expert panel
7737	NM_000104.4(CYP1B1):c.171G>A (p.Trp57Ter)	CYP1B1	Pathogenic	reviewed by expert panel
7742	NM_000104.4(CYP1B1):c.174del (p.Pro58_Leu59insTer)	CYP1B1	Pathogenic	no assertion criteria provided

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 6 · Orphanet: 12 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
CYP1B1	Definitive	Autosomal recessive	CYP1B1-related glaucoma with or without anterior segment dysgenesis	6

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
CYP1B1	Orphanet:708	Peters anomaly
CYP1B1	Orphanet:98976	Congenital glaucoma
CYP1B1	Orphanet:98977	Juvenile glaucoma
PXDN	Orphanet:289499	Congenital cataract microcornea with corneal opacity
PXDN	Orphanet:699850	2p25.3 microduplication syndrome
CPAMD8	Orphanet:519388	Autosomal recessive anterior segment dysgenesis
LTBP2	Orphanet:238763	Glaucoma secondary to spherophakia/ectopia lentis and megalocornea
LTBP2	Orphanet:3449	Weill-Marchesani syndrome
LTBP2	Orphanet:98976	Congenital glaucoma
LTBP3	Orphanet:2623	Geleophysic dysplasia
LTBP3	Orphanet:2899	Brachyolmia-amelogenesis imperfecta syndrome
LTBP3	Orphanet:969	Acromicric dysplasia

Cohort genes → proteins

5 cohort genes, 5 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	5

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
CYP1B1	HGNC:2597	ENSG00000138061	Q16678	Cytochrome P450 1B1	gencc,clinvar
PXDN	HGNC:14966	ENSG00000130508	Q92626	Peroxidasin homolog	clinvar
CPAMD8	HGNC:23228	ENSG00000160111	Q8IZJ3	C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8	clinvar
LTBP2	HGNC:6715	ENSG00000119681	Q14767	Latent-transforming growth factor beta-binding protein 2	clinvar
LTBP3	HGNC:6716	ENSG00000168056	Q9NS15	Latent-transforming growth factor beta-binding protein 3	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
CYP1B1	Cytochrome P450 1B1	A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins.
PXDN	Peroxidasin homolog	Catalyzes the two-electron oxidation of bromide by hydrogen peroxide and generates hypobromite as a reactive intermediate which mediates the formation of sulfilimine cross-links between methionine and hydroxylysine residues within an uncro…
LTBP2	Latent-transforming growth factor beta-binding protein 2	May play an integral structural role in elastic-fiber architectural organization and/or assembly.
LTBP3	Latent-transforming growth factor beta-binding protein 3	Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.4

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Complement	1	53.6×	0.056
Antibody/Immunoglobulin	1	5.8×	0.240
Other/Unknown	3	1.1×	0.608

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
CYP1B1	Other/Unknown	no		Cyt_P450, Cyt_P450_E_grp-I, Cyt_P450_CS
PXDN	Antibody/Immunoglobulin	yes	1.11.1.7	Cys-rich_flank_reg_C, VWF_dom, Leu-rich_rpt
CPAMD8	Complement	yes		Macroglobln_a2, Kazal_dom, MG2
LTBP2	Other/Unknown	no		EGF-type_Asp/Asn_hydroxyl_site, EGF, EGF-like_Ca-bd_dom
LTBP3	Other/Unknown	no		EGF-type_Asp/Asn_hydroxyl_site, EGF, EGF-like_Ca-bd_dom

Expression context

Cohort genes with no expression data: 0.

5 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	5
unknown	0

Top tissues across cohort

Tissue	Cohort genes
ascending aorta	2
descending thoracic aorta	2
thoracic aorta	2
cartilage tissue	1
pericardium	1
synovial joint	1
hair follicle	1
stromal cell of endometrium	1
tendon of biceps brachii	1
apex of heart	1
pancreatic ductal cell	1
right lung	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
CYP1B1	285	ubiquitous	marker	pericardium, cartilage tissue, synovial joint
PXDN	265	ubiquitous	marker	stromal cell of endometrium, hair follicle, tendon of biceps brachii
CPAMD8	227	broad	marker	apex of heart, pancreatic ductal cell, right lung
LTBP2	276	ubiquitous	marker	descending thoracic aorta, thoracic aorta, ascending aorta
LTBP3	279	broad	marker	descending thoracic aorta, thoracic aorta, ascending aorta

Protein interactions among cohort

Intra-cohort edges: 3.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
PXDN	9,915
CYP1B1	2,883
LTBP2	2,658
LTBP3	2,339
CPAMD8	692

Intra-cohort edges

A	B	Sources
CPAMD8	LTBP2	string_interaction
CPAMD8	LTBP3	string_interaction
CYP1B1	LTBP2	string_interaction

Structural data

PDB: 1 · AlphaFold-only: 4 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
CYP1B1	Q16678	2

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
PXDN	Q92626	80.43
CPAMD8	Q8IZJ3	72.99
LTBP3	Q9NS15	64.21
LTBP2	Q14767	58.33

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 13. Enrichment computed across 5 evidence-associated genes (4 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Elastic fibre formation	2	167.9×	3e-04	LTBP2, LTBP3
TGF-beta receptor signaling activates SMADs	2	163.1×	3e-04	LTBP2, LTBP3
Molecules associated with elastic fibres	2	154.3×	3e-04	LTBP2, LTBP3
Signaling by TGF-beta Receptor Complex	2	100.2×	5e-04	LTBP2, LTBP3
Defective CYP1B1 causes Glaucoma	1	2855.0×	9e-04	CYP1B1
Signaling by TGFB family members	2	57.7×	1e-03	LTBP2, LTBP3
Extracellular matrix organization	2	31.6×	0.003	LTBP2, LTBP3
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)	1	356.9×	0.005	CYP1B1
Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)	1	317.2×	0.005	CYP1B1
Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition	1	219.6×	0.006	PXDN
Crosslinking of collagen fibrils	1	142.8×	0.008	PXDN
Endogenous sterols	1	98.5×	0.011	CYP1B1
Signal Transduction	2	5.1×	0.051	LTBP2, LTBP3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
eye development	2	140.4×	0.005	PXDN, CPAMD8
benzene-containing compound metabolic process	1	3370.4×	0.006	CYP1B1
collagen fibril organization	2	89.9×	0.006	CYP1B1, PXDN
transforming growth factor beta receptor signaling pathway	2	63.6×	0.006	LTBP2, LTBP3
trabecular meshwork development	1	1685.2×	0.007	CYP1B1
obsolete membrane lipid catabolic process	1	842.6×	0.010	CYP1B1
endothelial cell-cell adhesion	1	842.6×	0.010	CYP1B1
steroid catabolic process	1	481.5×	0.010	CYP1B1
retinal blood vessel morphogenesis	1	481.5×	0.010	CYP1B1
positive regulation of mesenchymal stem cell differentiation	1	481.5×	0.010	LTBP3
toxin metabolic process	1	421.3×	0.010	CYP1B1
lung saccule development	1	421.3×	0.010	LTBP3
positive regulation of mesenchymal stem cell proliferation	1	421.3×	0.010	LTBP3
angiogenesis	2	25.0×	0.010	CYP1B1, PXDN
basement membrane assembly	1	374.5×	0.010	PXDN
omega-hydroxylase P450 pathway	1	306.4×	0.012	CYP1B1
blood vessel endothelial cell migration	1	280.9×	0.012	CYP1B1
negative regulation of cell adhesion mediated by integrin	1	259.3×	0.013	CYP1B1
supramolecular fiber organization	1	210.7×	0.013	LTBP2
positive regulation of bone resorption	1	198.3×	0.013	LTBP3
protein homotrimerization	1	198.3×	0.013	PXDN
negative regulation of bone mineralization	1	187.2×	0.013	LTBP3
retinal metabolic process	1	187.2×	0.013	CYP1B1
bone remodeling	1	187.2×	0.013	LTBP3
epoxygenase P450 pathway	1	177.4×	0.013	CYP1B1
intrinsic apoptotic signaling pathway in response to oxidative stress	1	168.5×	0.013	CYP1B1
sterol metabolic process	1	168.5×	0.013	CYP1B1
blood vessel morphogenesis	1	160.5×	0.013	CYP1B1
regulation of reactive oxygen species metabolic process	1	146.5×	0.013	CYP1B1
nitric oxide biosynthetic process	1	140.4×	0.013	CYP1B1

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 4

Druggability breadth: 1 of 5 evidence-associated genes (20%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
CYP1B1	PAZOPANIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
CYP1B1	22	4
PXDN	0	0
CPAMD8	0	0
LTBP2	0	0
LTBP3	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
PAZOPANIB	4	CYP1B1
INDACATEROL	4	CYP1B1
ESTRADIOL	4	CYP1B1
CANNABIDIOL	4	CYP1B1
BERBERINE	4	CYP1B1
MELATONIN	4	CYP1B1
ERYTHROMYCIN	4	CYP1B1
CARVEDILOL	4	CYP1B1
RESVERATROL	3	CYP1B1
BERGAPTEN	3	CYP1B1
QUERCETIN	3	CYP1B1
CANNABINOL	3	CYP1B1
LUTEOLIN	2	CYP1B1
FORMONONETIN	2	CYP1B1
FLAVONE	2	CYP1B1
2-METHOXYESTRADIOL	2	CYP1B1
PINOCEMBRIN	2	CYP1B1
KHELLIN	2	CYP1B1
BAICALEIN	2	CYP1B1
PTEROSTILBENE	2	CYP1B1
KAEMPFEROL	1	CYP1B1
PLUMBAGIN	1	CYP1B1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
CYP1B1	408	ADMET:281, Binding:127

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
PXDN	1.11.1.7	peroxidase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CYP1B1	408

Pharmacogenomics

Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

22 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
PAZOPANIB	4	CYP1B1
INDACATEROL	4	CYP1B1
ESTRADIOL	4	CYP1B1
CANNABIDIOL	4	CYP1B1
BERBERINE	4	CYP1B1
MELATONIN	4	CYP1B1
ERYTHROMYCIN	4	CYP1B1
CARVEDILOL	4	CYP1B1
RESVERATROL	3	CYP1B1
BERGAPTEN	3	CYP1B1
QUERCETIN	3	CYP1B1
CANNABINOL	3	CYP1B1
LUTEOLIN	2	CYP1B1
FORMONONETIN	2	CYP1B1
FLAVONE	2	CYP1B1
2-METHOXYESTRADIOL	2	CYP1B1
PINOCEMBRIN	2	CYP1B1
KHELLIN	2	CYP1B1
BAICALEIN	2	CYP1B1
PTEROSTILBENE	2	CYP1B1
KAEMPFEROL	1	CYP1B1
PLUMBAGIN	1	CYP1B1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	CYP1B1
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	2	PXDN, CPAMD8
E	Difficult family or no structure, no drug	2	LTBP2, LTBP3

Undrugged target profiles

4 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
PXDN	0	—
CPAMD8	0	—
LTBP2	0	—
LTBP3	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.